Answers are grounded in this paper and cite their sources.
Comparative trial analyzes adverse events in JAK inhibitors, highlighting distinct safety profiles for atopic dermatitis treatment.
Aim This study aimed to compare the safety profiles of abrocitinib, baricitinib, tofacitinib, and upadacitinib in the treatment of atopic dermatitis (AD) using adverse events (AEs) reported to the Food and Drug Adverse Event Reporting System (FAERS). Methods Data on Janus kinase (JAK) inhibitors were collected from the FAERS database covering the period from the first quarter of 2004 to the fourth quarter of 2024. Disproportionality analyses were performed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi‐item gamma Poisson shrinker (MGPS). Temporal distribution patterns were also evaluated. Results We analyzed 5231 JAK inhibitor‐related AEs extracted from the FAERS database. Abrocitinib, baricitinib, upadacitinib, and tofacitinib were associated with AEs in 26, 23, 27, and 21 SOCs, respectively. Additionally, preferred term‐level signal analysis showed that abrocitinib’s top AE signals were condition aggravated ( N = 122, ROR = 3.65, PRR = 3.53, EBGM = 3.47, IC = 1.80) and therapeutic product effect incomplete ( N = 106, ROR = 20.74, PRR = 20.00, EBGM = 17.71, IC = 4.15); baricitinib was linked to herpes zoster ( N = 6, ROR = 11.07, PRR = 10.91, EBGM = 10.82, IC = 3.44) and eczema herpeticum ( N = 6, ROR = 45.71, PRR = 45.00, EBGM = 43.27, IC = 5.44); tofacitinib had significant off‐label use signal ( N = 49, ROR = 22.94, PRR = 18.69, EBGM = 18.49, IC = 4.21); and upadacitinib’s top AE signal was acne ( N = 125, ROR = 8.19, PRR = 8.09, EBGM = 6.97, IC = 2.80). Abrocitinib, baricitinib, and upadacitinib showed positive death signals among the top 30 PTs, whereas tofacitinib did not. AEs displayed a distinct biphasic temporal pattern: AE frequency peaked in the initial treatment phase (0–30 days and 31–60 days), and cumulative AEs reached another peak during the mid‐ to long‐term phase of continuous treatment (181–360 days and > 360 days). Conclusion JAK inhibitors display distinct organ‐specific safety profiles in AD management.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: